论文部分内容阅读
Drug-eluting stents (DES) in clinical practice has changed the treatment perspective for bifurcation lesions, however, relatively high rates ofstent thrombosis and restenosis are still observed.Different DES may be associated with different outcomes.When treating bifurcated lesions with first-generation DES, sirolimus eluting stent might offer some advantages over the paclitaxel-eluting stent.Recently, a second generation of DES has been become available and has been shown to provide promising results when compared with a first-generation.